Seikagaku Corporation

Seikagaku Corporation is a research-driven pharmaceutical company specializing in glycoscience. Its defining feature is the combination of deep expertise in glycoscience products such as hyaluronic acid and a distinctive model without an in-house sales organization. The company focuses on glycobiology and has developed hyaluronic acid into products including ARTZ, the world's first joint-function improvement drug in 1987, ophthalmic surgery aids, and endotoxin testing reagents. It supplies markets in Japan and overseas through partnerships with pharmaceutical companies, making it a specialized R&D company with deep expertise in carbohydrates and hyaluronic acid.